‘Total TMS’
Education Conference
Transcranial Magnetic Stimulation
March 3 – 4, 2012
The Ritz-Carlton Hotel – Orlando, Florida
Presented by Neuronetics, Inc.
- Understand how the trend towards Interventional Psychiatry is impacting depression treatment outcomes
- Learn practical strategies for integrating NeuroStar TMS Therapy® as a standard of care in clinical psychiatric practice
Who Should Attend ‘Total TMS’?
Whether you are considering adding NeuroStar TMS Therapy® to your practice or are looking for methods of expanding your current NeuroStar TMS Therapy practice, “Total TMS” is the must-attend training event for psychiatrists and TMS care coordinators.
Starting Saturday morning and concluding by noon on Sunday, participants will be provided unique educational opportunities including hands on NeuroStar TMS Therapy treatment training, patient selection guidelines and practice integration best practices presented by an experienced clinical faculty of TMS Therapy experts.
During the clinical session, everything clicked on what was supposed to be happening with treatment…I really feel like I know what I am doing.
- Joshua Sussal, MD; Greenbelt, MD
(previous attendee)
I was debating having my own separate TMS practice and after Total TMS, I’ve decided I am definitely going to. The clinical session was excellent and very motivating.
- David Aversa, MD; Connecticut Psychiatric and Wellness Center (previous attendee)
Call 610-981-4110 to register for “Total TMS”
All trademarks are the property of Neuronetics, Inc.
Testimonials do not necessarily represent expected patient results as determined from NeuroStar clinical trials. Before reviewing, please note below the FDA-cleared indication for use and clinical trials data for NeuroStar TMS Therapy.
NeuroStar TMS Therapy is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication at or above the minimal effective dose and duration in the current episode.
Efficacy for NeuroStar TMS Therapy was established in a controlled clinical trial comparing active treatment with the NeuroStar TMS Therapy system to an inactive device. Patients treated with active NeuroStar TMS Therapy received an average reduction in their depression symptom score of 22.1% compared to a 9% average reduction in patients receiving inactive treatment (1).
NeuroStar TMS Therapy has not been studied in patients who have not received prior antidepressant treatment. Its effectiveness has also not been established in patients who have failed to receive benefit from two or more prior antidepressant medication at minimal effective dose and duration in the current episode.
The most common adverse event related to TMS is pain or discomfort at or near the treatment area during active TMS (2). There is a rare risk of seizure associated with TMS treatment (0.1% per acute treatment course).
NeuroStar TMS Therapy is available by prescription only. For full prescribing and safety information, please visit www.NeuroStar.com or call Neuronetics Customer Service at 1-877-600-7555.
1) Demitrack MA, Thase ME. Clinical significance of transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression: synthesis of recent data. Psychopharm Bull. 2009, 42(2): 5-38.
2) Janicak P, et al. Transcranial Magnetic Stimulation (TMS) in the Treatment of Major Depression: A Comprehensive Summary of Safety Experience from Acute Exposure, Extended Exposure and During Reintroduction Treatment. Journal of Clinical Psychiatry, February 2008.
